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Copyright © 2010 JCBN Summary Reduced coenzyme Q10 (CoQ10H2) is known as a potent antioxidant in biological
systems. However, it is not yet known whether CoQ9H2 could act as an antioxidant in human
cells. The aim of this study is to assess whether exogenously added CoQ9 can protect human
liver cells against injuries induced by a water-soluble radical initiator, 2,2'-azobis(2-
amidinopropane) dihydrochloride (AAPH) and a lipid-soluble radical initiator, 2,2'-azobis(2,4-
dimethylvaleronitrile) (AMVN). CoQ9-enriched cells were obtained by treatment of HepG2
cells with 10 µM CoQ9 liposomes for 24 h. CoQ9-enriched cells were exposed to 10 mM AAPH
and 500 µM AMVN over 4 h and 24 h, respectively. The loss of viability after treatment with
AAPH or AMVN was much less in CoQ9-enriched cells than in naive HepG2 cells. The
decrease in glutathione and the increase in thiobarbituric acid-reactive substance after treat-
ment with AAPH or AMVN were also suppressed in CoQ9-enriched cells. The incubation of
CoQ9-enriched cells with AAPH or AMVN led to a decrease in cellular CoQ9H2 and reciprocal
increase in cellular CoQ9 resulting from its antioxidant function. Taken together, it was
demonstrated for the first time that exogenously added CoQ9 could prevent oxidative stress-
mediated damage to human cells by virtue of its antioxidant activity.
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Introduction
Coenzyme Q (CoQ) is a quinone derivative with an
isoprenoid tail. CoQ homologs (CoQn) containing 1–13
isoprene units occur in nature, and in mammals the most
common forms contain 9 (CoQ9) and 10 (CoQ10) isoprene
units [1, 2]. CoQ9 is the predominant form in mouse and rat,
and CoQ10 is predominant in rabbit, guinea pig, dog, pig
and human [3]. As for the physiological significance of CoQn,
its role as an electron-carrying component of mitochondrial
respiratory chain is well established [4, 5]. A number of
in vitro and in vivo studies have revealed antioxidant func-
tion of CoQ10H2, reduced form of CoQ10 [6–16]. However,
it is not yet known whether CoQ9H2, a minor homolog in
human, could play a role as an antioxidant in human cells.
2,2'-Azobis(2-amidinopropane) dihydrochloride (AAPH)
and 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) are a
water-soluble and a lipid-soluble radical initiators, respec-
tively which undergo spontaneous thermal decomposition
to form carbon-centered radicals [17]. These radicals can
initiate a chain reaction of lipid peroxidation to generate
lipid peroxides in the presence of oxygen and polyunsatu-
rated fatty acids. AAPH and AMVN have therefore been
used to produce free-radical stresses.
We have reported that exogenously added CoQ10 canCoenzyme Q9 Prevents Human Liver Cell Injuries
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protected rat hepatocytes against cell death by AAPH [18].
However, it remains to be elucidated whether exogenously
added CoQ9 can prevent oxidative damage to human cells,
which have a considerable amount of CoQ10 but trace of
CoQ9. In the present study, we determined the sensitivities
of CoQ9-enriched human hepatic cells to oxidative stress
induced by AAPH and AMVN.
Materials and Methods
Chemicals
AAPH and dimyristoyl-phosphatidylcholine (DMPC) were
purchased from Wako Pure Chemical Ind. (Osaka, Japan).
AMVN was purchased from Tokyo Chemical Industry Co.,
Ltd. (Tokyo, Japan). Chromatographically pure CoQ9 and
CoQ10 were generous gifts from Eisai Co. (Tokyo, Japan).
Fetal calf serum (FCS) was purchased from PAA Labo-
ratories GmbH (Linz, Austria). Dulbecco’s modified eagle
medium (DMEM) was obtained from Nissui Pharmaceutical
Co., Ltd. (Tokyo, Japan). All other chemicals used were of
analytical grade.
Cell culture and establishment of CoQ9-enriched human
liver cells
HepG2 human hepatoma cell line was obtained from
Japan Health Science Foundation (Osaka, Japan), and grown
in DMEM supplemented with 10% heat-inactivated FCS,
2 mM glutamine and antibiotics (100 units/ml penicillin,
100 μg/ml streptomycin) at 37°C in a humidified incubator
with 5% CO2. Cells from passages 3–7 were used for the
experiments. The cells were seeded in 94-mm dishes at a
cell density of 5 × 105 cells/dish and incubated for 24 h at
37°C in an atmosphere of 5% CO2/95% air. After non-
adherent cells were removed by washing with culture
medium, attached cells were enriched with CoQ9 (see
below) before induction of free radical injuries.
Small unilamellar liposomes containing CoQ9 were pre-
pared by dissolving 17 mg of DMPC in 1 ml of ethanol
containing CoQ9 (1 mg/ml) at a CoQ9/DMPC molar ratio of
1:20. The solution was evaporated under N2 stream. The
resulting film was redissolved in 1.26 ml of phosphate-
buffered saline (PBS) to obtain 1 mM CoQ9, vortexed
vigorously, and sonicated for 3 min. HepG2 cells were
incubated at 37°C with varying concentrations of CoQ9
liposomes for different time periods to make CoQ9-enriched
human liver cells.
Experimental protocol
AAPH and AMVN were dissolved in PBS and dimethyl
sulfoxide (DMSO), respectively. CoQ9-enriched HepG2
cells and naive HepG2 cells were exposed to 10 mM
AAPH and 500 μM AMVN over 4 h and 24 h, respectively
to induce oxidative stress. The cells were harvested with
rubber policeman, washed with PBS twice, and resuspended
in PBS.
Measurement of CoQ9 and CoQ10
The cell suspension was transferred to a centrifuge tube
and centrifuged at 1,500 × g for 5 min. The resulting pellet
was washed with ice-cold PBS and stored at −80°C until
assayed. The determination of cellular oxidized and reduced
CoQ homologs (CoQ9, CoQ10, CoQ9H2 and CoQ10H2) was
carried out as described previously [3, 19, 20]. Briefly, the
frozen cells were homogenized with ice-cold water (1.3–
1.5 ml/ sample) under an atmosphere of nitrogen gas, and
then oxidized and reduced forms of CoQ9 and CoQ10 were
extracted with a mixture of 2 volumes of ethanol and 5
volumes of n-hexane to 1 volume of homogenate, and further
extracted two times. The n-hexane layers were collected
and evaporated under nitrogen gas. The residue was redis-
solved in ethanol, and subjected to high-performance liquid
chromatography (HPLC).
All standards used for HPLC were pure samples of CoQ9
and CoQ10. The reduced form of CoQ9 and CoQ10 were
prepared by reduction with sodium borohydride.
Cell Viability
The viability of cells was determined using a commer-
cially available WST-8 assay kit (Seikagaku Biobusiness
Co., Tokyo, Japan) according to the manufacture’s instruc-
tion as described previously [21]. The cells were seeded in
a 24-well plate at a cell density of 5 × 104 cells/well and
incubated for 24 h after treatment with CoQ9 liposomes,
and then exposed to 10 mM AAPH and 500 μM AMVN
over 4 h and 24 h, respectively. Cell viability was assessed
by measurement of the absorbance at 492 nm in a microplate
reader (Biotrak II, Amersham) after incubation of cells in
WST-8 solution for 1 h at 37°C.
Lipid peroxidation and glutathione assay
Cells were collected and washed with PBS twice. The
cells were resuspended in PBS and lysed by freezing and
thawing. Then, the cell lysates were homogenized in 0.05 M
phosphate buffer (0.2 M NaH2PO4, 0.2 M Na2HPO4, 0.2 M
Na-EDTA, pH 7.4) under N2 stream. Cellular lipid per-
oxidation was measured by a fuluorometric reaction with
thiobarbituric acid as previously described [15,  21,  22].
Lipid peroxide content was expressed as the amount of
malondialdehyde (MDA) equivalents using tetraethoxy-
propane as a standard.
Cellular reduced glutathione (GSH) contents were
determined fluorometrically using Thio-Glo1® as previously
described [23]. Briefly, cells treated with AAPH or AMVN
were harvested with rubber policeman and washed twice
with PBS. Thereafter cells were lysed by the same procedure
as that in lipid peroxidation assay. Immediately after addi-C. Kusumoto et al.
J. Clin. Biochem. Nutr.
246
tion of 10 μM Thio-Glo1® to the cell lysates, fluorescence
was measured in a CytoFluor II (Applied Biosystems, Foster
city, CA) fluorescence microplate reader using excitation
at 360 ± 40 nm and emission at 530 ± 25 nm.
Protein assay
Protein contents were determined by the method of
Bradford [24] with bovine serum albumin as a standard.
Statistical analysis
Data are expressed as means ± standard error (SE).
Changes in variables for different assays were analyzed
by Student’s t test or one-way ANOVA. Differences were
considered to be significant at p<0.05.
Results
Enrichment of CoQ9 in HepG2 cells with CoQ9 liposomes
To establish CoQ9-enriched HepG2 cells (referred to as
CoQ9-enriched cells below), intracellular concentration of
CoQ9, CoQ10, CoQ9H2 and CoQ10H2 was measured at 0, 4, 8,
12 or 24 h after treatment of naive HepG2 cells (referred to
as control cells below) with 10 μM CoQ9 liposomes (Fig. 1).
Cellular CoQ9 and CoQ9H2 levels increased in a time-
dependent manner and the levels reached a maximum 24 h
after addition of CoQ9 liposomes. In contrast, there were
few changes in cellular contents of CoQ10 and CoQ10H2
except for the CoQ10 content at 12 h.
We next examined whether CoQ9 liposomes were really
taken up by control cells, and whether they led to morpho-
logical changes of the cells. The cells were fixed in 10%
formalin, embedded in paraffin, sectioned, and stained with
Oil-red-O and hematoxylin. Thereafter, the specimen was
observed under a light microscope. Although CoQ9 lipo-
somes were time-dependently taken up by the cells as shown
by the increase in intracellular lipid droplets, there were no
morphological changes in the cytosol as well as the nucleus
until 24 h after treatment with CoQ9 liposomes (data not
shown).
Given these results, we used the cells incubated with
CoQ9 liposomes for 24 h as CoQ9-enriched cells in the
following experiments.
Resistance of CoQ9-enriched cells to oxidative stress
To determine the concentration of AAPH and AMVN
required to induce cell death in control cells, we treated
the cells with AAPH (1 to 10 mM) and AMVN (200 to
500 μM) for 4 h and 24 h, respectively. Both AAPH and
AMVN induced the decrease in cell viability in a dose-
dependent manner and the decrease reached a maximum at
10 mM and 500 μM, respectively (data not shown).
We next examined the time course of changes in cell
viability in control cells and CoQ9-enriched cells following
treatment with AAPH (10 mM) or AMVN (500 μM). The
viability of control cells after AAPH treatment decreased in
a time-dependent manner and was 24% of normal level after
4 h. On the other hand, the viability of CoQ9-enriched cells
after AAPH was significantly higher than that of control
cells during the incubation time period (Fig. 2A). Treatment
of control cells and CoQ9-enriched cells with AMVN
yielded similar results (Fig. 2B). These results suggested
that CoQ9-enriched cells are strongly resistant to oxidative
stress.
Lipid peroxidation in CoQ9-enriched cells exposed to
oxidative stress
We examined the effect of CoQ9 enrichment on lipid
peroxidation in control cells after AAPH (10 mM) exposure
(Fig. 3A). Thiobarbituric acid-reactive substance (TBARS)
level in control cells increased in a time-dependent manner
up to 2 h after AAPH, and thereafter reached the plateau.
The TBARS level was 2.5-fold of normal level at 4 h after
AAPH. In contrast, CoQ9-enriched cells kept normal
TBARS levels during the incubation time period. TBARS
level in control cells increased to 2.8-fold of normal level at
6 h after AMVN (500 μM) exposure, and thereafter reached
the plateau (Fig. 3B). However, CoQ9-enriched cells kept
almost normal TBARS levels during the incubation time
period.
Changes in GSH level in CoQ9-enriched cells exposed to
oxidative stress
Since GSH is the major intracellular reductant, we mea-
sured its concentration in control cells and CoQ9-enriched
Fig. 1. Changes in contents of CoQn and CoQnH2 in HepG2
cells after exposure to CoQ9 liposomes. HepG2 cells
were exposed to CoQ9 liposomes (10 μM) and harvested
after 4, 8, 12, or 24 h. Intracellular CoQ9, CoQ9H2,
CoQ10, and CoQ10H2 were measured by HPLC as de-
scribed in Materials and Methods. Data points represent
the means ± SE (n =3 ) .  * * p<0.01 vs CoQ9H2 at 24 h,
##p<0.01 vs CoQ9 at 24 h.Coenzyme Q9 Prevents Human Liver Cell Injuries
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cells over 4 h period of time after AAPH (10 mM) exposure
(Fig. 4A). Intracellular GSH in control cells significantly
decreased by 20% and 40% at 1 h and 2 h, respectively after
treatment with AAPH. The GSH level in CoQ9-enriched
cells was significantly higher than that in control cells at 1 h
after AAPH. When control cells were incubated with
500 μM AMVN over 24 h, cellular GSH content signifi-
cantly decreased by 20% at 12 h after AMVN (Fig. 4B). At
that time, the GSH content in CoQ9-enriched cells was
significantly higher than that in control cells.
Changes in the concentration of CoQ9, CoQ10, CoQ9H2 and
CoQ10H2 in CoQ9-enriched cells exposed to oxidative stress
To determine whether CoQ9H2 derived from intracellular
conversion of CoQ9 taken up acts as an antioxidant, we
measured the concentration of CoQ9, CoQ10, CoQ9H2 and
CoQ10H2 in CoQ9-enriched cells over 4 h period of time
after AAPH (10 mM) exposure (Fig. 5A). The concentration
of CoQ9H2 in CoQ9-enriched cells decreased linearly from 1
to 4 h after addition of AAPH, whereas that of CoQ9 tended
to increase reciprocally (Fig. 5A). In contrast, the concentra-
Fig. 2. Changes in cell viability in control cells and CoQ9-enriched cells following treatment with AAPH (A) or AMVN (B). HepG2
cells were incubated for 24 h in the absence (for control cells) or presence (for CoQ9-enriched cells) of CoQ9 liposomes
(10 μM), and then exposed to 10 mM AAPH and 500 μM AMVN over 4 h and 24 h, respectively. The cell viability was
analyzed using WST-8 assay kit. Data points represent the means ± SE (n =3 ) .  * * p<0.01 vs control cells at the same
incubation time.
Fig. 3. Changes in lipid peroxidation in control cells and CoQ9-enriched cells following treatment with AAPH (A) or AMVN (B). Con-
trol and CoQ9-enriched cells were incubated as described in the legend to Fig. 2. Cellular TBARS content was measured as de-
scribed in Materials and Methods. Data points represent the means ± SE (n =3 ) .  * p<0.05, **p<0.01 vs control cells at the
same incubation time.C. Kusumoto et al.
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tion of CoQ10H2 in CoQ9-enriched cells did not decrease
significantly during the incubation time period. When
CoQ9-enriched cells were incubated with 500 μM AMVN
over 24 h, the concentration of cellular CoQ9H2 decreased
linearly from 6 to 24 h after AMVN exposure with a
reciprocal increase in cellular CoQ9 (Fig. 5B). The concen-
tration of CoQ10H2, however, did not decrease significantly
over 24 h following AMVN addition.
Discussion
The present study demonstrated for the first time that
exogenously added CoQ9 was converted to CoQ9H2 in
human liver cells and subsequently acted as an antioxidant
to suppress lipid peroxidation in the cells, resulting in
protection of the cells against free radical-induced injuries.
Previous  in vivo and in vitro studies showed that
exogenously administered CoQ10 prevented a variety of
injuries associated with oxidative stress [9–16]. In an
experiment using endotoxicemic mice, administered CoQ10
was converted to CoQ10H2 in the liver, suppressed hepatic
lipid peroxidation, spared endogenous CoQ9H2, and increased
the survival rate of mice via its antioxidant function [12].
In this context, recent in vitro study has revealed that
exogenously added CoQ10H2 suppressed the secretion of
pro-inflammatory cytokine TNF-α as well as different
Fig. 4. Changes in GSH in control cells and CoQ9-enriched cells following treatment with AAPH (A) or AMVN (B). Control and
CoQ9-enriched cells were incubated as described in the legend to Fig. 2. Cellular GSH content was measured as described in
Materials and Methods. Data points represent the means ± SE (n =3 ) .  * p<0.05 vs control cells at the same incubation time.
Fig. 5. Changes in contents of CoQn and CoQnH2 in control cells and CoQ9-enriched cells following treatment with AAPH (A) or
AMVN (B). Control and CoQ9-enriched cells were incubated as described in the legend to Fig. 2. The concentrations of CoQn
and CoQnH2 in the cells were determined by HPLC as described in Materials and Methods. Data points represent the
means ± SE (n =3 ) .  * p<0.05 vs 0-h incubation time.Coenzyme Q9 Prevents Human Liver Cell Injuries
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chemokines in LPS-stimulated human monocytic THP-1
cells [25]. Furthermore, CoQ10 pretreatment was shown
to protect rat liver and kidney against injuries caused by
ischemia-reperfusion [10,  11], and orthotopic liver trans-
plantation [13], and also to protect canine heart against
reperfusion injury following cold preservation [14]. We have
shown that pretreatment with CoQ10 resulted in an increase
in hepatic CoQ10H2 and a marked reduction in hepatic lipid
peroxide content and plasma alanine aminotransferase
activity without affecting hepatic GSH after acetaminophen
injection [15]. In addition to the in vivo study, we have
demonstrated that exogenously added CoQ10 was actually
taken up by rat hepatocytes and reduced to CoQ10H2 in the
cells to protect against AAPH-induced cell death [18].
As described above, exogenously added CoQn has to be
reduced to CoQnH2 in the cells to exhibit its antioxidant
activity. Very important therefore is the presence of enzymes,
which can reduce CoQn and/or CoQn semiquinone radicals.
It is well known that mitochondrial CoQnH2 is efficiently
regenerated by the respiratory chain [26]. On the other hand,
to date, the following enzymes are proposed as reduction
enzymes for non-mitochondrial CoQn: NAD(P)H oxidoreduc-
tase (DT diaphorase) [27]; NADPH-dependent CoQ reduc-
tase [28]. The DT diaphorase is unique since it can directly
reduce CoQn by two-electron transfer without intermediate
formation of semiquinone, but it is less efficient for longer
isoprenoid side chain length, i.e. those with 9 or 10 isoprene
units [29]. NADH-dependent CoQ reductase is also a two-
electron reducing enzyme, located in the cytosol, and can
reduce CoQn with a long isoprenoid side chain such as
CoQ9 and CoQ10, to CoQnH2 [28]. Furthermore, lipoamide
dehydrogenase in the matrix surface of the mitochondria,
thioredoxine reductase 1 in the cytosol and nuclei, glutathione
reductase in the cytosol also could reduce CoQ10 to CoQ10H2
[28]. However, it remains unknown which reductase plays a
primary role in the reduction of CoQn.
We previously examined the difference in antioxidant
activity between endogenous CoQ9H2 and CoQ10H2 using
rat and guinea pig hepatocytes, which have CoQ9 and CoQ10,
respectively as a primary CoQ homolog [3]. We found
that endogenous CoQ9H2 constantly acted as a potent anti-
oxidant in rat as well as guinea pig hepatocytes exposed to
AAPH, whereas endogenous CoQ10H2 did so mainly in cells
such as guinea pig hepatocytes, in which CoQ10 was the
predominant CoQ homolog. Since endogenous CoQ9H2 is a
potent lipid-soluble antioxidant, supplementation with CoQ9
is strongly suggested to be a promising antidote for oxida-
tive stresses. Recent study based on the measurement of
CoQ9 and CoQ9H2 has reported that exogenously added
CoQ9 exhibits antioxidant activity in mice, which have CoQ9
as a major CoQ homolog [30].
In this study, we administered CoQ9 to the human liver
cells in which CoQ10 is predominant, and determined the
antioxidant activity of extrinsic CoQ9H2 in the cells exposed
to a water-soluble or a lipid-soluble radical initiator. We
used two kinds of azo compounds well known as radical
initiators, i.e. AAPH and AMVN [17]. AAPH generates
carbon radicals primarily and constantly through thermal
decomposition in the aqueous phase, and the radicals thus
formed react with oxygen rapidly to give peroxyl radicals.
This azo compound is therefore a useful tool for studying
the cell damage by extracellular free radicals. On the other
hand, AMVN is a lipid-soluble and water-insoluble azo
compound, and generates radicals initially within the lipid
region of the membranes. Therefore, we can investigate the
effect of extrinsic CoQ9H2 on two different kinds of free
radical-mediated damages. CoQ9-enriched cells were much
more resistant to extracellular free radical-mediated as well
as intramembranous free radical-mediated oxidative stress
compared with control cells. In this context, suppression of
lipid peroxidation was well correlated with the linear
decrease in abundant CoQ9H2 with reciprocal increase in
CoQ9 in CoQ9-enriched cells, indicating that a loss of
CoQ9H2 in the cells exposed to two different kinds of radical
initiators was caused by its acting as an antioxidant.
Moreover, CoQ10H2 content in CoQ9-enriched cells remained
unchanged during the exposure to the radical initiators,
suggesting that extrinsic CoQ9H2 could spare endogenous
CoQ10H2 by its serving as a primary antioxidant.
While CoQ10 administration was reported to enhance
endogenous CoQ9 by a mechanism that remains to be eluci-
dated [31], it has been shown that dietary CoQ10 did not
influence the endogenous biosynthesis of CoQ9 [32]. There
was no difference in the CoQ10 levels between control cells
and CoQ9-enriched cells. These discrepancies may be
ascribed to the differences in the duration of CoQ admin-
istration and/or in CoQ homologs administered. However,
the further studies should be required.
Extrinsic CoQ9H2 was the same potent antioxidant as
endogenous CoQ9H2 even when it was administered to the
cells that have CoQ10 as a predominant homolog. It is
evident from the studies using rodent models that exoge-
nously added CoQ10 is converted to CoQ10H2 and sub-
sequently plays an antioxidant role in various tissues, which
have CoQ9 as a predominant homolog. Therefore, CoQ9
supplementation for mammals that have mainly CoQ10 is
potentially one of promising antioxidative procedures like
CoQ10 supplementation. The previous study has revealed
that CoQ10 is taken up from the intestine into the circulation
with a low rate in rats, and only about 2–4% can be re-
covered [32]. Accordingly, in the case of CoQ9 supple-
mentation in vivo, absorption efficiency of CoQ9 from the
intestine in CoQ10-predominant mammals has to be eluci-
dated. Furthermore, CoQ9 taken up by the cells has to be
delivered to the cellular compartments appropriately. In this
connection, saposin B, a CoQ10-binding and transfer protein,C. Kusumoto et al.
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has been shown to also bind to CoQ9 [33].
In conclusion, the present study has shown that exoge-
nously added CoQ9 protects human cells against oxidative
stress via its potent antioxidant activity.
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